A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

Trial Profile

A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PROTEC
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results of a subgroup analysis assessing the effectiveness of delayed-release dimethyl fumarate on annualized relapse rate in newly diagnosed MS patients presented at the 69th Annual Meeting of the American Academy of Neurology
    • 08 Mar 2017 Planned End Date changed from 1 Mar 2016 to 1 Apr 2019.
    • 08 Mar 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top